Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication

Inclusion Criteria: * Female or male subject ≥ 18 years of age, * With a diagnosis of acute DVT treated with VKA with issues for at least the 4 previous weeks (issues are assessed on medical judgment) * Who intends to start rivaroxaban for treatment of deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT * With anticoagulation therapy planned for at least 3 months Exclusion Criteria: * Contra indication to the use of Xarelto as described in the Summary of Product Characteristics (SmPC); key contra indications are: * Hypersensitivity to the active substance or to any of the excipients listed in SmPC section 6.1. * Lesion or condition at significant risk of major bleeding * Concomitant treatment with any other anticoagulant agent * Clinically significant active bleeding * Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C * Pregnancy and breast feeding